Class plaintiffs said executives padded Walmart's pharmacy revenue by encouraging pharmacists to fill opioid prescriptions with questionable legitimacy. Those actions, the complaint said, led to a stock price drop when the U.S. Justice Department sued to stop overprescription.
January 21, 2021 at 05:00 PM
1 minute read
The original version of this story was published on Delaware Business Court Insider
A new layer has been added to Walmart’s pending opioid-related litigation, this time with investors going after the company.
In a securities class action suit filed Wednesday in the U.S. District Court for the District of Delaware, an investor alleged executives knowingly padded Walmart Inc.’s pharmacy revenue by encouraging pharmacists to fill opioid prescriptions with questionable legitimacy.
Presented by BigVoodoo
Join General Counsel and Senior Legal Leaders at the Premier Forum Designed For and by General Counsel from Fortune 1000 Companies
This conference brings together the industry's most influential & knowledgeable real estate executives from the net lease sector.
Join the industry's top owners, investors, developers, brokers & financiers at THE MULTIFAMILY EVENT OF THE YEAR!
Duane Morris LLP seeks a highly motivated junior associate to join its dynamic and growing Labor and Employment Class Action group in Chicag...
Duane Morris LLP seeks a full-time staff litigation attorney who has practiced between 3-5 years. Experience will include drafting motions, ...
Duane Morris LLP has an immediate opening for a senior level, highly motivated litigation associate to join its dynamic and growing Employme...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
Walmart store in Baltimore. Aug. 9, 2020. Photo: Diego M. Radzinschi/ALM
